Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days.

bioRxiv : the preprint server for biology·2026

Same author

Comparison of Ebola virus infection routes and resulting disease in animal models.

Journal of virology·2026

Same author

Griffithsin-mediated inhibition of cellular entry of hemorrhagic fever viruses and insights into its mechanisms.

Journal of virology·2026

Same author

Transcriptional signatures of rapid protection from Sudan virus infection by a single dose of a vesicular stomatitis virus-based vaccine.

PLoS pathogens·2026

Same author

Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection.

Vaccine·2026

Same author

Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge.

bioRxiv : the preprint server for biology·2026

Same journal

Dengue Virus Evasion of Host Innate Immunity.

Annual review of virology·2026

Same journal

Geminivirus-Induced Reprogramming of Plant Defense Mechanisms: Molecular Insights and Research Frontiers.

Annual review of virology·2026

Same journal

The Evolution of Dengue Virus in India.

Annual review of virology·2026

Same journal

Studying the Deep Evolution of Viruses in the Era of Artificial Intelligence Structure Prediction.

Annual review of virology·2026

Same journal

Viral Pleomorphism: How Virion Structure Guides Infection and Adaptation.

Annual review of virology·2026

Same journal

Targeting Herpesvirus Recombination Proteins for Antiviral Therapy.

Annual review of virology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 18, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Ebola Virus: Pathogenesis and Countermeasure Development.

Wakako Furuyama¹, Andrea Marzi¹

¹Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana 59840, USA;

Annual Review of Virology

|October 1, 2019

Summary

This summary is machine-generated.

Ebola virus (EBOV) outbreaks necessitate rapid medical countermeasures. This review details EBOV pathogenesis, vaccine development, and treatments for Ebola virus disease (EVD).

Keywords:

Ebola virus Ebola virus disease animal model clinical trials filovirus vaccines

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Related Experiment Videos

Last Updated: Jan 18, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Area of Science:

Virology
Epidemiology
Public Health

Background:

Ebola virus (EBOV) causes severe hemorrhagic fever with high fatality rates.
The 2013-2016 West Africa epidemic underscored the urgent need for effective Ebola virus disease (EVD) countermeasures.
Limited licensed treatments or vaccines were available during the initial stages of the epidemic.

Purpose of the Study:

To review the pathogenesis of EBOV.
To summarize the current status of EVD vaccine development.
To outline current treatment strategies for EVD.

Main Methods:

Literature review of EBOV pathogenesis.
Summary of preclinical and clinical vaccine trials for EBOV.
Analysis of treatment approaches for EVD.

Main Results:

Experimental drugs and vaccines showed preclinical efficacy and advanced to clinical trials.
Ring-vaccination strategies were employed using candidate vaccines.
Several therapeutic and prophylactic interventions progressed towards licensure.

Conclusions:

The EBOV epidemic accelerated the development of novel vaccines and treatments.
Ongoing research is crucial for preparedness against future EVD outbreaks.
A combination of rapid response, advanced therapeutics, and vaccination is key to controlling EVD.